Albumin treatment reduces neurological deficit and protects blood-brain barrier integrity after acute intracortical hematoma in the rat

Ludmila Belayev, Isabel Saul, Raul Busto, Kristine Danielyan, Alexey Vigdorchik, Larissa Khoutorova, Myron Ginsberg

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background and Purpose - Acute intracerebral hemorrhage (ICH) is a common and severe form of stroke. To date, medical management of ICH has had scant impact on morbidity and mortality. Because albumin therapy is markedly neuroprotective in preclinical models of ischemic stroke, and because ischemic and hemorrhagic stroke share several common injury mechanisms, we hypothesized that albumin therapy might also benefit ICH. Methods - Acute intracortical hematoma was produced in anesthetized, normothermic rats by the single stereotaxic injection of 50 μL of autologous, nonheparinized whole blood over 5 minutes. Separate animal groups were treated either with 25% human albumin, 1.25 g/kg, or with intravenous saline vehicle at 60 minutes after ICH. Neurobehavior was quantified sequentially over the next 2 to 7 days. Damage to the blood-brain barrier was assessed at 2 days after ICH by fluorometric measurement of Evans blue extravasation in dissected brain regions. Results - High-grade neurological deficits were present in all rats at 50 minutes after ICH (score 10.3±0.2, mean±SEM [maximal score 12]). Albumin-treated rats showed improved neuroscores relative to saline-treated animals beginning within hours of treatment and persisting throughout the 7-day survival period. At 3 and 7 days, mean total neuroscores of the albumin group were 38% to 43% lower than in saline-treated animals. Perihematomal Evans blue discoloration was readily evident in saline-treated ICH rats but was reduced by albumin treatment. Hemispheric Evans blue content ipsilateral to the hematoma was reduced by 49% by albumin treatment (albumin 93.9±13.3 versus saline 184.7±33.7 mg/g, P<0.05). Hematoma volume and brain swelling were not affected by albumin treatment. Conclusions - Prompt albumin therapy improves neurological function and blood-brain barrier integrity after acute intracortical hematoma. These observations have important potential clinical implications.

Original languageEnglish
Pages (from-to)326-331
Number of pages6
JournalStroke
Volume36
Issue number2
DOIs
StatePublished - Feb 1 2005

Fingerprint

Blood-Brain Barrier
Hematoma
Albumins
Cerebral Hemorrhage
Evans Blue
Therapeutics
Stroke
Brain Edema
Morbidity
Injections
Survival
Mortality
Wounds and Injuries
Brain

Keywords

  • Acute therapy
  • Albumin
  • Basic science
  • Blood-brain barrier
  • Hemorrhage, intracranial
  • Neuroprotectants
  • Neuroprotection
  • Neuroprotective agents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Albumin treatment reduces neurological deficit and protects blood-brain barrier integrity after acute intracortical hematoma in the rat. / Belayev, Ludmila; Saul, Isabel; Busto, Raul; Danielyan, Kristine; Vigdorchik, Alexey; Khoutorova, Larissa; Ginsberg, Myron.

In: Stroke, Vol. 36, No. 2, 01.02.2005, p. 326-331.

Research output: Contribution to journalArticle

Belayev, Ludmila ; Saul, Isabel ; Busto, Raul ; Danielyan, Kristine ; Vigdorchik, Alexey ; Khoutorova, Larissa ; Ginsberg, Myron. / Albumin treatment reduces neurological deficit and protects blood-brain barrier integrity after acute intracortical hematoma in the rat. In: Stroke. 2005 ; Vol. 36, No. 2. pp. 326-331.
@article{ffc15532d2b54d98b086d3d2861b7948,
title = "Albumin treatment reduces neurological deficit and protects blood-brain barrier integrity after acute intracortical hematoma in the rat",
abstract = "Background and Purpose - Acute intracerebral hemorrhage (ICH) is a common and severe form of stroke. To date, medical management of ICH has had scant impact on morbidity and mortality. Because albumin therapy is markedly neuroprotective in preclinical models of ischemic stroke, and because ischemic and hemorrhagic stroke share several common injury mechanisms, we hypothesized that albumin therapy might also benefit ICH. Methods - Acute intracortical hematoma was produced in anesthetized, normothermic rats by the single stereotaxic injection of 50 μL of autologous, nonheparinized whole blood over 5 minutes. Separate animal groups were treated either with 25{\%} human albumin, 1.25 g/kg, or with intravenous saline vehicle at 60 minutes after ICH. Neurobehavior was quantified sequentially over the next 2 to 7 days. Damage to the blood-brain barrier was assessed at 2 days after ICH by fluorometric measurement of Evans blue extravasation in dissected brain regions. Results - High-grade neurological deficits were present in all rats at 50 minutes after ICH (score 10.3±0.2, mean±SEM [maximal score 12]). Albumin-treated rats showed improved neuroscores relative to saline-treated animals beginning within hours of treatment and persisting throughout the 7-day survival period. At 3 and 7 days, mean total neuroscores of the albumin group were 38{\%} to 43{\%} lower than in saline-treated animals. Perihematomal Evans blue discoloration was readily evident in saline-treated ICH rats but was reduced by albumin treatment. Hemispheric Evans blue content ipsilateral to the hematoma was reduced by 49{\%} by albumin treatment (albumin 93.9±13.3 versus saline 184.7±33.7 mg/g, P<0.05). Hematoma volume and brain swelling were not affected by albumin treatment. Conclusions - Prompt albumin therapy improves neurological function and blood-brain barrier integrity after acute intracortical hematoma. These observations have important potential clinical implications.",
keywords = "Acute therapy, Albumin, Basic science, Blood-brain barrier, Hemorrhage, intracranial, Neuroprotectants, Neuroprotection, Neuroprotective agents",
author = "Ludmila Belayev and Isabel Saul and Raul Busto and Kristine Danielyan and Alexey Vigdorchik and Larissa Khoutorova and Myron Ginsberg",
year = "2005",
month = "2",
day = "1",
doi = "10.1161/01.STR.0000152949.31366.3d",
language = "English",
volume = "36",
pages = "326--331",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Albumin treatment reduces neurological deficit and protects blood-brain barrier integrity after acute intracortical hematoma in the rat

AU - Belayev, Ludmila

AU - Saul, Isabel

AU - Busto, Raul

AU - Danielyan, Kristine

AU - Vigdorchik, Alexey

AU - Khoutorova, Larissa

AU - Ginsberg, Myron

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Background and Purpose - Acute intracerebral hemorrhage (ICH) is a common and severe form of stroke. To date, medical management of ICH has had scant impact on morbidity and mortality. Because albumin therapy is markedly neuroprotective in preclinical models of ischemic stroke, and because ischemic and hemorrhagic stroke share several common injury mechanisms, we hypothesized that albumin therapy might also benefit ICH. Methods - Acute intracortical hematoma was produced in anesthetized, normothermic rats by the single stereotaxic injection of 50 μL of autologous, nonheparinized whole blood over 5 minutes. Separate animal groups were treated either with 25% human albumin, 1.25 g/kg, or with intravenous saline vehicle at 60 minutes after ICH. Neurobehavior was quantified sequentially over the next 2 to 7 days. Damage to the blood-brain barrier was assessed at 2 days after ICH by fluorometric measurement of Evans blue extravasation in dissected brain regions. Results - High-grade neurological deficits were present in all rats at 50 minutes after ICH (score 10.3±0.2, mean±SEM [maximal score 12]). Albumin-treated rats showed improved neuroscores relative to saline-treated animals beginning within hours of treatment and persisting throughout the 7-day survival period. At 3 and 7 days, mean total neuroscores of the albumin group were 38% to 43% lower than in saline-treated animals. Perihematomal Evans blue discoloration was readily evident in saline-treated ICH rats but was reduced by albumin treatment. Hemispheric Evans blue content ipsilateral to the hematoma was reduced by 49% by albumin treatment (albumin 93.9±13.3 versus saline 184.7±33.7 mg/g, P<0.05). Hematoma volume and brain swelling were not affected by albumin treatment. Conclusions - Prompt albumin therapy improves neurological function and blood-brain barrier integrity after acute intracortical hematoma. These observations have important potential clinical implications.

AB - Background and Purpose - Acute intracerebral hemorrhage (ICH) is a common and severe form of stroke. To date, medical management of ICH has had scant impact on morbidity and mortality. Because albumin therapy is markedly neuroprotective in preclinical models of ischemic stroke, and because ischemic and hemorrhagic stroke share several common injury mechanisms, we hypothesized that albumin therapy might also benefit ICH. Methods - Acute intracortical hematoma was produced in anesthetized, normothermic rats by the single stereotaxic injection of 50 μL of autologous, nonheparinized whole blood over 5 minutes. Separate animal groups were treated either with 25% human albumin, 1.25 g/kg, or with intravenous saline vehicle at 60 minutes after ICH. Neurobehavior was quantified sequentially over the next 2 to 7 days. Damage to the blood-brain barrier was assessed at 2 days after ICH by fluorometric measurement of Evans blue extravasation in dissected brain regions. Results - High-grade neurological deficits were present in all rats at 50 minutes after ICH (score 10.3±0.2, mean±SEM [maximal score 12]). Albumin-treated rats showed improved neuroscores relative to saline-treated animals beginning within hours of treatment and persisting throughout the 7-day survival period. At 3 and 7 days, mean total neuroscores of the albumin group were 38% to 43% lower than in saline-treated animals. Perihematomal Evans blue discoloration was readily evident in saline-treated ICH rats but was reduced by albumin treatment. Hemispheric Evans blue content ipsilateral to the hematoma was reduced by 49% by albumin treatment (albumin 93.9±13.3 versus saline 184.7±33.7 mg/g, P<0.05). Hematoma volume and brain swelling were not affected by albumin treatment. Conclusions - Prompt albumin therapy improves neurological function and blood-brain barrier integrity after acute intracortical hematoma. These observations have important potential clinical implications.

KW - Acute therapy

KW - Albumin

KW - Basic science

KW - Blood-brain barrier

KW - Hemorrhage, intracranial

KW - Neuroprotectants

KW - Neuroprotection

KW - Neuroprotective agents

UR - http://www.scopus.com/inward/record.url?scp=12844253661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12844253661&partnerID=8YFLogxK

U2 - 10.1161/01.STR.0000152949.31366.3d

DO - 10.1161/01.STR.0000152949.31366.3d

M3 - Article

C2 - 15637329

AN - SCOPUS:12844253661

VL - 36

SP - 326

EP - 331

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 2

ER -